drugset / Trial / NCT00004042
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
Phase 1
Completed
24 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody F19 in treating patients who have advanced or metastatic cancer.
Timeline
- Start
- 1998-11
- Primary completion
- 2001-07
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F19 | Monoclonal antibody | — | Intravenous |